{"commentary":{"count":69,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":63,"youtube":3,"podcast":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02613819\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"FASTRACK II","nct_id":"NCT02613819","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=fastrack-ii-nct02613819. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"FASTRACK II","arms":[{"description":"Stereotactic Ablative Body Radiotherapy (SABR)\n\nTreatment schedule 1: 26 Gray (Gy) in 1 fraction, for tumours of less than or equal to 4cm in size.\n\nTreatment schedule 2: 42 Gray (Gy) in 3 fractions, for tumours of greater than 4cm in size","label":"Stereotactic Ablative Body Radiotherapy","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-11-24","type":"ACTUAL"},"conditions":["Renal Cell Carcinoma"],"enrollment":{"count":71,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"SABR","type":"RADIATION"}],"last_update":"2026-09-29","lead_sponsor":"Trans Tasman Radiation Oncology Group","official_title":"Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney, a Phase II Clinical Trial (FASTRACK II)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2025-11-24","type":"ACTUAL"},"primary_outcomes":[{"measure":"Activity and efficacy of SABR measured by Freedom from local progression assessed by RECIST Criteria","timeFrame":"12mths post treatment"}],"references":[{"citation":"Siva S, Ali M, Hardcastle N, Kron T, Higgs B, Foroudi F, Ruben J, Appu S, Martin J, Sridharan S, Montgomery R, Davey R, Lin C, Shaw M, Chander S, Sidhom M, Vanneste BGL, Murphy DG, Lawrentschuk N, Pryor D, Wood S, Moon D, Bressel M. Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials. Lancet Oncol. 2026 Jun;27(6):721-728. doi: 10.1016/S1470-2045(26)00170-1. Epub 2026 May 17.","pmid":"42144019","type":"DERIVED"},{"citation":"Siva S, Pryor D, Martin J, Hardcastle N, Moon D, Kron T, Higgs B, Foroudi F, Ruben J, Sridharan S, Montgomery R, Davey R, Lin C, Shaw M, Lawrentschuk N, Appu S, Vanneste BGL, Hofman MS, Murphy DG, De Abreu Lourenco R, Mancuso P, Brook NR, Raman A, Wong LM, Sidhom M, Wood S, Ali M, Bressel M. Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study. Lancet Oncol. 2026 Jun;27(6):711-720. doi: 10.1016/S1470-2045(26)00091-4. Epub 2026 May 17.","pmid":"42144018","type":"DERIVED"},{"citation":"Siva S, Bressel M, Sidhom M, Sridharan S, Vanneste BGL, Davey R, Montgomery R, Ruben J, Foroudi F, Higgs B, Lin C, Raman A, Hardcastle N, Hofman MS, De Abreu Lourenco R, Shaw M, Mancuso P, Moon D, Wong LM, Lawrentschuk N, Wood S, Brook NR, Kron T, Martin J, Pryor D; FASTRACK II Investigator Group. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial. Lancet Oncol. 2024 Mar;25(3):308-316. doi: 10.1016/S1470-2045(24)00020-2.","pmid":"38423047","type":"DERIVED"},{"citation":"Siva S, Chesson B, Bressel M, Pryor D, Higgs B, Reynolds HM, Hardcastle N, Montgomery R, Vanneste B, Khoo V, Ruben J, Lau E, Hofman MS, De Abreu Lourenco R, Sridharan S, Brook NR, Martin J, Lawrentschuk N, Kron T, Foroudi F. TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II. BMC Cancer. 2018 Oct 23;18(1):1030. doi: 10.1186/s12885-018-4916-2.","pmid":"30352550","type":"DERIVED"}],"start_date":{"date":"2016-07"},"study_type":"INTERVENTIONAL","title":"Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney","url":"https://clinicaltrials.gov/study/NCT02613819"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/fastrack-ii-nct02613819"}